Cargando…

The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer

BACKGROUND: Little is known about the relationship between preoperative body mass index and need for adjuvant radiation therapy (RT) following radical prostatectomy. The goal of this study was to evaluate the utility of body mass index in predicting adverse clinical outcomes which require adjuvant R...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamoah, Kosj, Zeigler-Johnson, Charnita M., Jeffers, Abra, Malkowicz, Bruce, Spangler, Elaine, Park, Jong Y., Whittemore, Alice, Rebbeck, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966583/
https://www.ncbi.nlm.nih.gov/pubmed/27473687
http://dx.doi.org/10.1186/s12885-016-2572-y
_version_ 1782445400661164032
author Yamoah, Kosj
Zeigler-Johnson, Charnita M.
Jeffers, Abra
Malkowicz, Bruce
Spangler, Elaine
Park, Jong Y.
Whittemore, Alice
Rebbeck, Timothy R.
author_facet Yamoah, Kosj
Zeigler-Johnson, Charnita M.
Jeffers, Abra
Malkowicz, Bruce
Spangler, Elaine
Park, Jong Y.
Whittemore, Alice
Rebbeck, Timothy R.
author_sort Yamoah, Kosj
collection PubMed
description BACKGROUND: Little is known about the relationship between preoperative body mass index and need for adjuvant radiation therapy (RT) following radical prostatectomy. The goal of this study was to evaluate the utility of body mass index in predicting adverse clinical outcomes which require adjuvant RT among men with organ-confined prostate cancer (PCa). METHODS: We used a prospective cohort of 1,170 low-intermediate PCa risk men who underwent radical prostatectomy and evaluated the effect of body mass index on adverse pathologic features and freedom from biochemical failure (FFbF). Clinical and pathologic variables were compared across the body mass index groups using an analysis of variance model for continuous variables or χ(2) for categorical variables. Factors related to adverse pathologic features were examined using logistic regression models. Time to biochemical recurrence was compared across the groups using a log-rank survivorship analysis. Multivariable analysis predicting biochemical recurrence was conducted with a Cox proportional hazards model. RESULTS: Patients with elevated body mass index (defined as body mass index ≥25 kg/m(2)) had greater extraprostatic extension (p = 0.004), and positive surgical margins (p = 0.01). Elevated body mass index did not correlate with preoperative risk groupings (p = 0.94). However, when compared with non-obese patients (body mass index <30 kg/m(2)), obese patients (body mass index ≥30 kg/m(2)) were much more likely to have higher rate of adverse pathologic features (p = 0.006). In patients with low- and intermediate- risk disease, obesity was strongly associated with rate of pathologic upgrading of tumors (p = 0.01 and p = 0.02), respectively. After controlling for known preoperative risk factors, body mass index was independently associated with ≥2 adverse pathologic features (p = 0.002), an indicator for adjuvant RT as well as FFbF (p = 0.001). CONCLUSIONS: Body mass index of ≥30 kg/m(2) is independently associated with adverse pathologic features, which is an indicator for additional RT, particularly in patients with low-intermediate risk disease. Future studies may determine if this select group of patients may be best treated with definitive RT to reduce toxicity from additional RT following radical prostatectomy. We propose including body mass index in clinical decision-making for appropriate treatment recommendation for patients with low-intermediate risk PCa.
format Online
Article
Text
id pubmed-4966583
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49665832016-07-30 The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer Yamoah, Kosj Zeigler-Johnson, Charnita M. Jeffers, Abra Malkowicz, Bruce Spangler, Elaine Park, Jong Y. Whittemore, Alice Rebbeck, Timothy R. BMC Cancer Research Article BACKGROUND: Little is known about the relationship between preoperative body mass index and need for adjuvant radiation therapy (RT) following radical prostatectomy. The goal of this study was to evaluate the utility of body mass index in predicting adverse clinical outcomes which require adjuvant RT among men with organ-confined prostate cancer (PCa). METHODS: We used a prospective cohort of 1,170 low-intermediate PCa risk men who underwent radical prostatectomy and evaluated the effect of body mass index on adverse pathologic features and freedom from biochemical failure (FFbF). Clinical and pathologic variables were compared across the body mass index groups using an analysis of variance model for continuous variables or χ(2) for categorical variables. Factors related to adverse pathologic features were examined using logistic regression models. Time to biochemical recurrence was compared across the groups using a log-rank survivorship analysis. Multivariable analysis predicting biochemical recurrence was conducted with a Cox proportional hazards model. RESULTS: Patients with elevated body mass index (defined as body mass index ≥25 kg/m(2)) had greater extraprostatic extension (p = 0.004), and positive surgical margins (p = 0.01). Elevated body mass index did not correlate with preoperative risk groupings (p = 0.94). However, when compared with non-obese patients (body mass index <30 kg/m(2)), obese patients (body mass index ≥30 kg/m(2)) were much more likely to have higher rate of adverse pathologic features (p = 0.006). In patients with low- and intermediate- risk disease, obesity was strongly associated with rate of pathologic upgrading of tumors (p = 0.01 and p = 0.02), respectively. After controlling for known preoperative risk factors, body mass index was independently associated with ≥2 adverse pathologic features (p = 0.002), an indicator for adjuvant RT as well as FFbF (p = 0.001). CONCLUSIONS: Body mass index of ≥30 kg/m(2) is independently associated with adverse pathologic features, which is an indicator for additional RT, particularly in patients with low-intermediate risk disease. Future studies may determine if this select group of patients may be best treated with definitive RT to reduce toxicity from additional RT following radical prostatectomy. We propose including body mass index in clinical decision-making for appropriate treatment recommendation for patients with low-intermediate risk PCa. BioMed Central 2016-07-29 /pmc/articles/PMC4966583/ /pubmed/27473687 http://dx.doi.org/10.1186/s12885-016-2572-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yamoah, Kosj
Zeigler-Johnson, Charnita M.
Jeffers, Abra
Malkowicz, Bruce
Spangler, Elaine
Park, Jong Y.
Whittemore, Alice
Rebbeck, Timothy R.
The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
title The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
title_full The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
title_fullStr The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
title_full_unstemmed The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
title_short The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
title_sort impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966583/
https://www.ncbi.nlm.nih.gov/pubmed/27473687
http://dx.doi.org/10.1186/s12885-016-2572-y
work_keys_str_mv AT yamoahkosj theimpactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT zeiglerjohnsoncharnitam theimpactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT jeffersabra theimpactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT malkowiczbruce theimpactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT spanglerelaine theimpactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT parkjongy theimpactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT whittemorealice theimpactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT rebbecktimothyr theimpactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT yamoahkosj impactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT zeiglerjohnsoncharnitam impactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT jeffersabra impactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT malkowiczbruce impactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT spanglerelaine impactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT parkjongy impactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT whittemorealice impactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer
AT rebbecktimothyr impactofbodymassindexontreatmentoutcomesforpatientswithlowintermediateriskprostatecancer